Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. MainPointe is an emerging OTC pharmaceutical company that brings added leverage to our NEXAFED business, commented Bob Jones, Ac
By a News Reporter-Staff News Editor at Health& Medicine Week Specialty-specific health information technology leader Modernizing Medicine, Inc. and global leader in skin health, Galderma Laboratories, L.P., announced a collaboration to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider...
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Ryoo, Je Phil; Chu, Chun Kwong; Wang, Zheng, filed on July 20, 2015, was published online on February 28, 2017. The patent's assignee for patent number 9579295 is NAL PHARMACEUTICAL GROUP LIMITED. Migraine headache
Washington, DC- Congressman Jose E. Serrano today introduced the Protecting Our Kids Act of 2017, which would direct the Food and Drug Administration to require pharmaceutical companies to include dosage delivery devices, commonly known as flow restrictors, when selling over-the-counter medicines. This legislation will help keep our children safe b
Jose E. Serrano, D- N.Y., issued the following news release:. Congressman Jose E. Serrano today introduced the Protecting Our Kids Act of 2017, which would direct the Food and Drug Administration to require pharmaceutical companies to include dosage delivery devices, commonly known as flow restrictors, when selling over-the-counter medicines.
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the results of a clinical study evaluating the impact of SebuDerm? gel in the treatment of mild to moderate facial and scalp seborrheic
All comments should be identified with the OMB control number 0910-0677. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 10 A63, 11601 Landsdown St., North Bethesda, MD 20852, PRAStaff@fd
The war on drugs is a never-ending game of whack-a-mole. That has been the story since President Richard Nixon declared war on drugs in June 1971. Since 2011, the state of Alabama has restricted the over-the-counter sale of some cold medicines that can be broken down and used to make methamphetamine.
Hutchison China MediTech Limited announced today that on Monday March 13, 2017, it filed its annual report on Form 20- F with the U.S. Securities and Exchange Commission. Target 2018 launch in China as the first approved treatment for third-line CRC patients; 8 drug candidates now in 30 active clinical trials around the world with four pivotal Phas
Teligent, Inc. is a specialty generic pharmaceutical company. All references to " Teligent," the "Company," "we," "us," and "our" refer to Teligent, Inc. Our mission is to become a leader in the specialty generic pharmaceutical market. Under our own label, we currently market and sell generic topical and branded generic injectable pharmaceutical pr
Nutra Pharma Corporation, a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, announced today that Stockguru.com will be releasing an interview with Nutra Pharma's CEO through their website. "I appreciate the oppor
Statements below regarding future events or performance are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results could be quite different from those expressed or implied by the forward-looking statements. Factors that could affect results are discussed more fully under the Item
Tetra Bio-Pharma Inc., announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US $5.5 billion. The total ocular..
March 13 As the nationwide war on opioid addiction wages on, a Frederick- based electroceutical company may have brought one solution to the market. BioElectronics Corp., which operates out of the Frederick Innovative Technology Center Inc., recently received over-the-counter clearance from the Federal Drug Administration for its flagship product
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, will share scientific data at the 55 th Annual Meeting of the Society of Toxicology, which will suggest the company's novel topical gel BPX-01 delivers acne-fighting medication to the target area safely without systemic side effects.
Novartis Kisqali receives FDA approval as first-line treatment for HR+/ HER2- metastatic breast cancer in combination with any aromatase inhibitor. Novartis International AG/ Novartis Kisqali receives FDA approval as first-line. treatment for HR+/ HER2- metastatic breast cancer in combination with any aromatase inhibitor.
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss safety issues associated with over-the-counter analgesic combination products used for upset stomach and hangover indications under the...
By a News Reporter-Staff News Editor at Pharma Business Week Innovus Pharmaceuticals, Inc.,, announced that the Company will release its fourth quarter and full year 2016 financial results and provide a corporate update on Monday, March 6, 2017, after the close of the U.S. financial markets. About Innovus Pharmaceuticals, Inc. Headquartered in Sa
The US Food and Drug Administration has approved Kisqali in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. "Kisqali is emblematic of the innovation that Novar
The acquisition of Vitel is expected to transform OncBioMune into a revenue-generating international pharmaceutical company with a more diverse product line with a particularly deep reach throughout Mexico, Central and Latin America, and relationships across Europe and Asia. Vitel founder Manuel Cosme Odabachian, an expert in drug licensing,...
Vitel is a revenue-stage Mexico- based pharmaceutical company that develops and commercializes specialty drugs in Mexico and other Latin American countries. To induce the Vitel Stockholders to enter into the Contribution Agreement and as a condition to close the transactions set forth in that agreement, the Company, the Vitel Stockholders, Dr. Head
Use this report to:- Receive information concerning the dynamics and forecasts in the OTC drugs and dietary supplements market- Receive information pertaining to the major regional trends in the global OTC drugs and dietary supplements market- Identify the key initiatives and strategies to control regulatory and supply chain issues for market gro
By a News Reporter-Staff News Editor at Pharma Business Week- Perrigo Company plc, a leading global provider of Quality Affordable Healthcare Products , announced that Ron Winowiecki, Senior Vice President, Business Finance, has been appointed acting Chief Financial Officer, effective immediately, following the resignation of Judy L. Brown, Exe
Sunovion Pharmaceuticals Inc. today announced that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration to expand the indication for its antiepileptic drug APTIOM to include use as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in children four years of age and older.
Perth, Australia, Mar 13, 2017 MMJ PhytoTech Limited is pleased to provide the following sales and operations update on its wholly-owned Switzerland- based subsidiary, Satipharm AG. Satipharm has secured Pharmaceutical Central Numbers for its 10 mg and 50 mg Gelpell-CBD Microgel Capsules, enabling both products to be sold in all pharmacies throug